Dosing & Uses
Dosage Forms & Strengths
tablet
- 25mg
- 100mg
- 200mg
HIV Infection
Treatment of HIV-1 infection in combination with ≥2 additional antiretroviral agents in treatment-experienced patients exhibiting viral replication with documented non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance
200 mg PO q12hr
Renal Impairment
No dosage adjustment required
Hepatic Impairment
Mild-to-moderate (Child-Pugh class A or B): No dosage adjustment required
Severe (Child-Pugh class C): Pharmacokinetics have not been evaluated
Dosage Forms & Strengths
tablet
- 25mg
- 100mg
- 200mg
HIV Infection
Treatment of HIV-1 infection in combination with ≥2 additional antiretroviral agents in treatment-experienced patients ≥2 years exhibiting viral replication with documented non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance
<2 years: Safety and efficacy not established
2 to <18 years and ≥10 kg
- 10 to <20 kg: 100 mg PO q12hr
- 20 to <25 kg: 125 mg PO q12hr
- 25 to <30 kg: 150 mg PO q12hr
- ≥30 kg: 200 mg PO q12hr
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Adverse Effects
>10%
Rash (16.9%)
Nausea (13.9%)
Increased LDL (13%)
1-10%
GI disorders (2.3-5.2%)
Fatigue (3.3%)
Peripheral neuropathy (4%)
Increased creatinine (2%)
Diarrhea (2%)
<1%
Stevens-Johnson syndrome
Erythema multiforme
Angina
Angioedema
Toxic epidermal necrolysis (including reports of fatalities)
Hypersensitivity reactions (including cases of hepatic failure)
Postmarketing Reports
Immune system disorders: Severe hypersensitivity reactions including DRESS and cases of hepatic failure
Musculoskeletal and connective tissue disorders: Rhabdomyolysis
Skin and subcutaneous tissue disorders: Fatal cases of toxic epidermal necrolysis
Warnings
Contraindications
None
Cautions
Hypersensitivity
Risk of severe skin reactions (eg, Stevens-Johnson Syndrome, erythema multiforme, toxic epidermal necrolysis)
Hypersensitivity reactions including drug rash with eosinophilia and systemic symptoms (DRESS) reported; characterized by rash, constitutional findings, and sometimes organ dysfunction; discontinue if severe rash develops and initiate appropriate therapy
Risk of immune reconstitution syndrome
50% decrease in absorption when administered under fasting conditions: only take with meal
Drug interactions overview
- Etravirine is a CYP3A, CYP2C9, and CYP2C19 substrate; coadministration with CYP3A, CYP2C9, and CYP2C19 inhibitors or inducers may alter efficacy or adverse reaction profile of etravirine
- Etravirine is a CYP3A inducer and CYP2C9, CYP2C19 and P-glycoprotein (Pgp) inhibitor; coadministration of CYP3A, CYP2C9, CYP2C19, or P-gp substrate may alter the efficacy or toxicity of the coadministered drug(s)
Pregnancy & Lactation
Pregnancy
An ART pregnancy registry has been established (1-800-258-4263); prospective pregnancy data from the Antiviral Pregnancy Registry (APR) not sufficient to adequately assess risk of birth defects or miscarriage
Etravirine use during pregnancy evaluated in a limited number of individuals as reported by the APR, and available data show 1 birth defect in 66 first trimester exposures to etravirine-containing regimens
Lactation
The Centers for Disease Control and Prevention recommend HIV-1-infected mothers not breastfeed their infants to avoid risking postnatal transmission of HIV
Based on limited data, etravirine has been shown to be present in human breast milk
No data on the effects of etravirine on the breastfed infant, or the effects of etravirine on milk production Because of potential for HIV-1 transmission (in HIV-negative infants), developing viral resistance (in HIV-positive infants), and adverse reactions in breastfed infants similar to those seen in adults, instruct mothers not to breastfeed during treatment
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1
Binds directly to reverse transcriptase and blocks RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic sites
Absorption
AUC: 4380 ng·hr/mL
Peak plasma time: 2.5-4 hr
Effects of food
- AUC to etravirine was decreased by about 50% when administered under fasting conditions, as compared to when administered following a meal
- Meals contained a total caloric content ranging from 345-1160 kilocalories (17-70 grams fat)
Distribution
Protein Bound: 99.9%
Metabolism
Metabolized in liver by CYP3A4, CYP2C9, and CYP2C19
Induces CYP3A4
Inhibits CYP2C9 and CYP2C19
Elimination
Half-Life: 41 hr +/- 20 hr
Excretion: Feces (93.7% [81.2% unchanged]); urine (1.2% [86.4% unchanged])
Administration
Oral Administration
Take ONLY after a meal
Swallow tablets whole
Unable to swallow tablet whole
- Place tablet(s) in 5 mL (1 teaspoon) of water, or at least enough liquid to cover the medication; stir until water looks milky
- Add ~15 mL (1 tablespoon) of liquid (eg, water, orange juice, or milk) Do not place tablets in orange juice or milk without first adding water
- Avoid use of warm (temperature > 104°F [>40°C]) or carbonated beverages
- Drink mixture immediately
- Rinse glass several times with liquid and completely swallow the rinse each time to ensure patient takes the entire dose
Storage
Tablets: Store at 25°C (77°F); with excursions permitted to 15-30°C (59-86°F)
Images
Patient Handout
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.